Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 334 (Erenumab) PK in Pediatric Migraine
NCT03499119Phase 1Completed
- Sponsor
- Amgen
- Start
- May 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of erenumab in migraine (2 cohorts), sponsored by Amgen. Primary endpoints: Time to Maximum Concentration at Day 85, Maximum Observed Concentration at Day 85 and 7 more. Started May 2018; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03499119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499119.